Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is projected to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.50 per share and revenue of $136.7920 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $53.11 million during the quarter. Catalyst Pharmaceuticals had a return on equity of 40.78% and a net margin of 37.36%. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $21.36 on Wednesday. The company has a market cap of $2.61 billion, a PE ratio of 12.95, a price-to-earnings-growth ratio of 0.85 and a beta of 0.79. The stock has a 50-day moving average of $20.38 and a 200-day moving average of $21.86. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $26.58.

Catalyst Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 1st that allows the company to buyback $200.00 million in shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, CEO Richard J. Daly sold 22,970 shares of the firm’s stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total value of $473,641.40. Following the completion of the sale, the chief executive officer owned 226,794 shares in the company, valued at approximately $4,676,492.28. This trade represents a 9.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steve Miller sold 115,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.28, for a total value of $2,332,200.00. Following the completion of the sale, the insider owned 949,663 shares of the company’s stock, valued at $19,259,165.64. This represents a 10.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 243,970 shares of company stock worth $4,927,241 over the last 90 days. Insiders own 10.40% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently modified their holdings of CPRX. E Fund Management Co. Ltd. lifted its position in shares of Catalyst Pharmaceuticals by 8.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 871 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Catalyst Pharmaceuticals by 3,227.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,444 shares of the biopharmaceutical company’s stock worth $270,000 after buying an additional 12,070 shares in the last quarter. Norges Bank acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $299,000. Creative Planning raised its holdings in shares of Catalyst Pharmaceuticals by 19.6% in the 2nd quarter. Creative Planning now owns 16,385 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 2,689 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in shares of Catalyst Pharmaceuticals by 7.3% in the 2nd quarter. Quantbot Technologies LP now owns 17,903 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 1,224 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, October 12th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.